COLL — Collegium Pharmaceutical Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapNeutral

Annual income statement for Collegium Pharmaceutical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	310	277	464	567	631
Cost of Revenue
Gross Profit	180	151	214	326	377
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	254	259	431	423	473
Operating Profit	56.2	17.6	33.3	143	159
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	27.6	-3.37	-28.8	75.7	98.6
Provision for Income Taxes
Net Income After Taxes	26.8	71.5	-25	48.2	69.2
Net Income Before Extraordinary Items
Net Income	26.8	71.5	-25	48.2	69.2
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	26.8	76.2	-25	54	75.1
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.761	1.98	-0.046	1.78	2.48